Effects of flurbiprofen axetil on oxidative stress and serum VCAM-1, IMA in patients with lung cancer during perioperative period

doi:10.3877/cma.j.issn.1674-6902.2021.01.010

Abstract

Abstract:

Objective

To study the effects of flurbiprofen axetil on oxidative stress and serum VCAM-1, IMA in patients with lung cancer during perioperative period.

Methods

76 patients with lung cancer treated in our hospital from March 2017 to September 2019 were randomly divided into study group (39 cases) and control group (37 cases). in the control group, midazolam was used for anesthesia induction and maintenance, and flurbiprofen axetil was given for anesthesia induction and maintenance in the study group. Before operation(T₀), 2 h after the beginning of operation(T₁) and 24 h after the completion of operation(T₂), the contents of glutathione peroxidase (GSH-PX), superoxide dismutase(SOD), malondialdehyde (MDA), hydrogen peroxide(H₂O₂), hydroxyl radical(OH), superoxide anion(), vascular cell adhesion molecule-1(VCAM-1) and ischemia-modified albumin (IMA) were determined by enzyme-linked immunosorbent assay. The serum BUN, serum Cr, the ratio of urine β₂ microglobulin/Cr and urine NAG/Cr were determined; The blood Treg and IL-10 levels were measured by flow cytometry.

Results

Compared to T₀, the GSH-PX and SOD levels of the two groups decreased (P<0.05), the MDA, H₂O₂, OH and levels increased at T₁ and T₂, and the decrease or increase of above parameters were significantly lower in the study group at the same time than in the control group (P<0.05); Compared to T₀, the VCAM-1 level of peripheral blood in the two groups decreased at T₁ and T₂, and the VCAM-1 level of the patients in the study group was significantly lower than that in the control group (P<0.05); The level of peripheral blood IMA in the two groups increased, and the IMA of the study group was significantly lower than that in the control group at the same time (P<0.05). The serum BUN, serum Cr, the ratio of urine β₂ microglobulin/Cr and urine NAG/Cr increased in both groups, and the increase of study group was significantly lower than that of control group (P<0.05); The Treg and IL-10 levels of the two groups were decreased, and the study group was significantly higher than that of the control group (P<0.05).

Conclusion

Flurbiprofen axetil can effectively resist oxidative stress in patients with lung cancer during perioperative period, reduce the VCAM-1 level in serum, control the increase of IMA level, and reduce lung injury, and it can also effectively alleviate the immune response caused by surgery and has good renal protection effect.

Key words: Flurbiprofen axetil, Bronchogenic carcinoma, Oxidative stress, Vascular cell adhesion molecule-1, Ischemia modifies albumin

Zhuangguang Qiu, Xuemei Wei, Yu Tang, Zhixin Xu. Effects of flurbiprofen axetil on oxidative stress and serum VCAM-1, IMA in patients with lung cancer during perioperative period[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(01): 53-57.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2021.01.010

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2021/V14/I01/53

Figures/Tables 4

References 30

1	钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2	Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446.
3	Xiang X, Yuan X, Lian Y, et al. Effect of oxycodone hydrochloride combined with flurbiprofen axetil for intravenous patient-controlled analgesia in lower abdominal patients: A randomized trial[J]. Medicine, 2018, 97(7): e9911.
4	Xiao X, Zhang Q, Ouyang Z, et al. Comparison of perioperative flurbiprofen axetil or celecoxib administration for pain management after total-knee arthroplasty: A retrospective study[J]. Medicine, 2018, 97(37): e12391.
5	Sheng-Jie Z, Ling Z, Mei-Qin C, et al. Changes and significance of adhesion molecule and cell proliferation index before and after chemotherapy in non-small cell lung cancer[J]. Chinese Journal of Health Laboratory Technology, 2018, 28(14): 1750-1752,1756.
6	Chen WC, Lin CY, Kuo SJ, et al. Resistin enhances VCAM-1 expression and monocyte adhesion in human osteoarthritis synovial fibroblasts by Inhibiting MiR-381 Expression through the PKC, p38, and JNK Signaling Pathways[J]. Cells, 2020, 9(6): E1369.
7	Tayman M, Canan Önder, Şivge Kurgan, et al. A Novel systemic indicator of periodontal tissue damage: ischemia modified albumin[J]. Comb Chem High Throughput Screen, 2018, 21(8): 544-549.
8	孔　岚，卢锡华. 右美托咪啶对胸腔镜肺癌根治术患者围手术期炎症反应及细胞免疫功能的影响[J]. 中华医学杂志，2018, 98(36): 2929-2932.
9	何三江. 右美托咪定全凭静脉麻醉对肺癌患者围术期外周血单核细胞HMGB-1表达、氧化应激与细胞免疫因子的影响[J]. 临床肺科杂志，2018, 23(12): 136-140.
10	Liu Z, Liu Y, Gu Y, et al. Met-enkephalin inhibits ROS production through Wnt/β-catenin signaling in the ZF4 cells of zebrafish[J]. Fish Shellfish Immunol, 2019, 88: 432-440.
11	杨晓琴，马陈斌，张　艳. 对比丙泊酚与咪达唑仑应用于颅内脑膜瘤切除术患者对血流动力学、脑保护的影响[J]. 药学与临床研究，2018, 26(5): 339-342.
12	倪旭青，汪炜健. 氟比洛芬酯对老年患者腹腔镜胆囊术后认知功能及炎症因子的影响[J]. 医药导报，2019, 38(6): 735-738.
13	Ozer MK, Bilgic S, Armagan I, et al. Thymoquinone protection from amikacin induced renal injury in rats[J]. Biotech Histochem, 2019, 95(2): 1-8.
14	Wang R, Hu H, Hu S, et al. β2-microglobulin is an independent indicator of acute kidney injury and outcomes in patients with intracerebral hemorrhage[J]. Medicine, 2020, 99(8): e19212.
15	张文蓉，王苏建，董燕芬，等. 血清Hcy、Cys-C、NAG及mALB对妊娠期糖尿病患者早期肾损伤的检验诊断价值[J]. 实用医学杂志，2018, 34(23): 3986-3989.
16	Bin L, Anesthesiology DO. Effect of protective mechanical ventilation combined with flurbiprofen axetil on the lung of patients undergoing radical esophagectomy and its effects on the levels of inflammatory factors, β-endofibrin and prostaglandin[J]. Clin Med, 2019, 39(11): 16-18.
17	Zaiss DM, Minutti CM, Knipper JA. Immune and non-immune-mediated roles of regulatory T-cells during wound healing[J]. Immunology, 2019, 157(3): 190-197.
18	Mahzuz K, Kingsley CI, Bushell AR, et al. Alloantigen-induced CD25⁺ CD4⁺ regulatory T cells can develop in vivo from CD25^- CD4⁺ precursors in a thymus-independent process[J]. J Immunol, 2019, 172(2): 923-928.
19	Ramóna P, Emese U, Timea L, et al. Glucocorticoid hormone differentially modulates the in vitro expansion and cytokine profile of thymic and splenic Treg cells[J]. Immunobiol, 2019, 224(2): 285-295.
20	张小侠，张美玲，杨明珍. CD8～+CD28～-调节性T细胞及血小板特异性自身抗体在免疫性血小板减少症中的表达[J]. 安徽医科大学学报，2019, 9: 1405-1410.
21	徐叶进，唐新月，杨　敏，等. 白细胞介素10基因修饰的树突状细胞对肝纤维化小鼠的治疗作用及其机制[J]. 中华内科杂志，2018, 57(11): 835-840.
22	Bin L, Anesthesiology DO. Effect of protective mechanical ventilation combined with flurbiprofen axetil on the lung of patients undergoing radical esophagectomy and its effects on the levels of inflammatory factors, β-endofibrin and prostaglandin[J]. Clin Med, 2019, 39(11): 16-18.
23	Mok CC, Soliman S, Ho LY, et al. Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis[J]. Arthritis Res Ther, 2018, 20(1): 6.
24	吴军霞，马阿火. 柳氮磺吡啶联合糖皮质激素对老年溃疡性结肠炎患者疗效、免疫功能、血清炎症因子及肠黏膜NF-κB、ICAM-1、VCAM-1的影响[J]. 中国老年学杂志，2018, 38(7): 1630-1632.
25	Zhou Z, Zhou Q, Wu X, et al. VCAM-1 secreted from cancer-associated fibroblasts enhances the growth and invasion of lung cancer cells through AKT and MAPK signaling[J]. Cancer Letters, 2020, 473: 62-73.
26	孙丽平，孔一卜，刘　璐，等. 益气固本胶囊对哮喘小鼠模型ICAM-1、VCAM-1水平的影响[J]. 时珍国医国药，2019, 30(3): 59-61.
27	胡继成，柴小青，疏树华，等. 氟比洛芬酯联合肺保护性通气对胸腔镜肺癌根治术病人术后细胞免疫功能的影响[J]. 中华麻醉学杂志，2019, 39(1): 18-22.
28	袁　芬，吴群群. 血清缺血修饰白蛋白在多囊卵巢综合征患者中的变化及临床意义[J]. 中国医师进修杂志，2020, 43(4): 309-312.
29	吕淑杰，翟羽佳. 缺血修饰白蛋白在急性心肌梗死早期诊断中的价值分析[J]. 中国地方病防治杂志，2018, 33(2): 187-189.
30	侯莉莉，陈　琳，杨晓玫，等. 氟比洛芬酯后处理对大鼠局灶性脑缺血再灌注时血脑屏障通透性的影响[J]. 中华麻醉学杂志，2020, 40(7): 813-816.

参　数	组别	例数	T₀	T₁	T₂
GSH-Px(U/ml)	研究组	39	36.56±6.84	25.37±4.78	36.46±6.39
	对照组	37	36.47±6.58	18.96±5.28	25.03±3.92
	t值		0.062	5.092	9.998
	P值		0.951	<0.001	<0.001
SOD(U/ml)	研究组	39	45.65±5.72	37.03±5.37	44.24±4.09
	对照组	37	45.19±5.82	30.27±6.22	35.23±4.27
	t值		0.370	5.394	9.992
	P值		0.713	<0.001	<0.001
MDA(nmol/L)	研究组	39	5.05±0.69	7.78±1.49	5.02±0.44
	对照组	37	5.03±0.77	9.53±1.47	6.57±0.36
	t值		0.133	5.483	7.878
	P值		0.894	<0.001	<0.001
H₂O₂(mmol/L)	研究组	39	34.66±6.04	55.34±7.65	34.48±4.09
	对照组	37	34.26±6.37	76.98±8.85	39.45±5.34
	t值		0.229	12.130	4.845
	P值		0.766	<0.001	<0.001
OH(U/ml)	对照组	39	341.23±59.23	415.23±55.45	356.37±38.64
	研究组	37	340.99±58.34	568.22±54.34	384.23±40.63
	t值		0.019	12.922	3.258
	P值		0.985	<0.001	0.002
(U/L)	对照组	39	110.96±16.43	157.35±23.43	113.36±31.78
	研究组	37	111.03±17.66	177.56±22.46	133.87±33.46
	t值		0.019	4.083	2.914
	P值		0.985	<0.001	0.005

参　数	组别	例数	T₀	T₁	T₂
GSH-Px(U/ml)	研究组	39	36.56±6.84	25.37±4.78	36.46±6.39
	对照组	37	36.47±6.58	18.96±5.28	25.03±3.92
	t值		0.062	5.092	9.998
	P值		0.951	<0.001	<0.001
SOD(U/ml)	研究组	39	45.65±5.72	37.03±5.37	44.24±4.09
	对照组	37	45.19±5.82	30.27±6.22	35.23±4.27
	t值		0.370	5.394	9.992
	P值		0.713	<0.001	<0.001
MDA(nmol/L)	研究组	39	5.05±0.69	7.78±1.49	5.02±0.44
	对照组	37	5.03±0.77	9.53±1.47	6.57±0.36
	t值		0.133	5.483	7.878
	P值		0.894	<0.001	<0.001
H₂O₂(mmol/L)	研究组	39	34.66±6.04	55.34±7.65	34.48±4.09
	对照组	37	34.26±6.37	76.98±8.85	39.45±5.34
	t值		0.229	12.130	4.845
	P值		0.766	<0.001	<0.001
OH(U/ml)	对照组	39	341.23±59.23	415.23±55.45	356.37±38.64
	研究组	37	340.99±58.34	568.22±54.34	384.23±40.63
	t值		0.019	12.922	3.258
	P值		0.985	<0.001	0.002
(U/L)	对照组	39	110.96±16.43	157.35±23.43	113.36±31.78
	研究组	37	111.03±17.66	177.56±22.46	133.87±33.46
	t值		0.019	4.083	2.914
	P值		0.985	<0.001	0.005

参　数	组别	例数	T₀	T₁	T₂
VCAM-1(ng/ml)	研究组	39	264±21	251±18	241±20
	对照组	37	263±22	260±23	250±21
	t值		0.216	2.021	2.035
	P值		0.830	0.046	0.045
IMA(ng/ml)	对照组	39	11.56±3.65	14.36±4.26	16.89±6.33
	研究组	37	11.87±2.36	17.15±4.76	21.39±6.35
	t值		0.438	2.864	3.219
	P值		0.662	0.005	0.001

参　数	组别	例数	T₀	T₁	T₂
VCAM-1(ng/ml)	研究组	39	264±21	251±18	241±20
	对照组	37	263±22	260±23	250±21
	t值		0.216	2.021	2.035
	P值		0.830	0.046	0.045
IMA(ng/ml)	对照组	39	11.56±3.65	14.36±4.26	16.89±6.33
	研究组	37	11.87±2.36	17.15±4.76	21.39±6.35
	t值		0.438	2.864	3.219
	P值		0.662	0.005	0.001

参　数	组别	例数	T₀	T₁	T₂
血Cr(μmol/L)	研究组	39	63.19±11.00	82.87±15.74	64.26±14.73
	对照组	37	63.27±10.99	105.03±17.36	88.46±14.57
	t值		0.034	6.201	7.659
	P值		0.973	<0.001	<0.001
尿β2-MG/Cr(mg/mmol)	研究组	39	0.0161±0．0023	0.2765±0．0156	0.1027±0．0563
	对照组	37	0.0160±0．0022	0.5166±0．0203	0.1748±0．0746
	t值		0.206	54.842	5.059
	P值		0.837	<0.001	<0.001
尿NAG/Cr(U/mmol)	研究组	39	0.02461±0．0141	0.1526±0．0114	0.0269±0．0174
	对照组	37	0.02467±0．0134	0.2417±0．0153	0.0463±0．0142
	t值		0.020	30.622	5.664
	P值		0.984	<0.001	<0.001
血BUN(mmol/L)	研究组	39	4.82±0.62	11.35±1.87	8.17±2.31
	对照组	37	4.78±0.65	13.46±1.76	10.47±2.37
	t值		0.292	5.388	4.557
	P值		0.771	<0.001	<0.001

Please choose a citation manager

Content to export